Are we missing dementia with Lewy bodies?: a case report

2018 ◽  
Vol 26 (4) ◽  
pp. 381-383
Author(s):  
Deborah Wearne ◽  
Amanda Genetti ◽  
Sam Restifo ◽  
Alina Harriss

Objectives: We aim to explore the importance of early diagnosis of dementia with Lewy bodies in order to facilitate effective psychiatric management. We present a case where delayed diagnosis stemming from an atypical presentation illustrates the complex issues involved in identifying and treating this type of dementia. Conclusions: We discuss the difficulty of diagnosis of this disorder in the absence of obvious memory dysfunction or parkinsonian symptoms. We use the case to draw attention to the limited availability of certain investigations and treatment options in Australia.

Author(s):  
J. Eric Ahlskog

Patients, spouses, families, and caregivers dealing with dementia face a host of complex issues, particularly when they must confront Dementia with Lewy Bodies or Parkinson's Disease. Until now there has been no guidebook for the general public to help navigate these challenging disorders. In Dementia with Lewy Bodies and Parkinson's Disease Dementia, Dr. J. Eric Ahlskog draws on 30 years of clinical and research work at Mayo Clinic to arm patients and families with crucial information that will enable them to work in tandem with their doctors. A diagnosis of dementia can be devastating, leaving families and caregivers struggling with a loved one's radically-impaired thinking and memory. When dementia is coupled with Parkinson's, which will develop in Parkinson's patients that live long enough, or with Lewy Bodies, which is the second leading cause of dementia behind Alzheimer's, the difficulties become even more daunting. And while these disorders are all too common, most people have little solid information about them. Too often doctors cannot spend the necessary time answering questions or discussing the specific challenges and treatments for these kinds of dementia during office visits. Arriving for a doctor appointment knowing the issues and treatment options beforehand gives patients and families an important head start. Dr. Ahlskog clearly explains all aspects of these disorders, their causes, symptoms, most effective drug treatments, proper doses, and which medications to avoid. He also discusses the complications that can arise in treating these conditions, given the variety of available medications and their possible side effects and interactions. While a cure does not yet exist, in this accessible, highly informative guidebook, Dr. Ahlskog shows that optimal medical treatment can markedly improve the quality of life for both patients and family.


1996 ◽  
Vol 17 (4) ◽  
pp. S159
Author(s):  
I.G. McKeith ◽  
R.H. Perry ◽  
E.K. Perry ◽  
P.G. Ince

Author(s):  
Hiroyuki Arai ◽  
Makoto Higuchi ◽  
Nobuyuki Okamura ◽  
Xia Sheng Hu ◽  
Toshifumi Matsui ◽  
...  

2016 ◽  
Vol 23 (8) ◽  
pp. 1322-1328 ◽  
Author(s):  
S. Favaretto ◽  
U. Walter ◽  
C. Baracchini ◽  
S. Pompanin ◽  
C. Bussè ◽  
...  

2019 ◽  
Vol 69 (3) ◽  
pp. 839-847 ◽  
Author(s):  
Maurizio Gallucci ◽  
Carola Dell’Acqua ◽  
Franco Boccaletto ◽  
Chiara Fenoglio ◽  
Daniela Galimberti ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Radoslaw Magierski ◽  
Tomasz Sobow

Dementia with Lewy bodies (DLB) is considered to be the second most frequent primary degenerative dementing illness after Alzheimer’s disease (AD). DLB, together with Parkinson’s disease (PD), Parkinson’s disease with dementia (PDD) belong toα-synucleinopathies—a group of neurodegenerative diseases associated with pathological accumulation of theα-synuclein protein. Dementia due to PD and DLB shares clinical symptoms and neuropsychological profiles. Moreover, the core features and additional clinical signs and symptoms for these two very similar diseases are largely the same. Neuroimaging seems to be a promising method in differential diagnosis of dementia studies. The development of imaging methods or other objective measures to supplement clinical criteria for DLB is needed and a method which would accurately facilitate diagnosis of DLB prior to death is still being searched. Proton magnetic resonance spectroscopy (1H-MRS) provides a noninvasive method of assessing anin vivobiochemistry of brain tissue. This review summarizes the main results obtained from the application of neuroimaging techniques in DLB cases focusing on1H-MRS.


2020 ◽  
Vol 8 (1) ◽  
Author(s):  
Barbara E. Spencer ◽  
Robin G. Jennings ◽  
Chun C. Fan ◽  
James B. Brewer

Abstract In the clinical diagnosis of dementia with Lewy bodies, distinction from Alzheimer’s disease is suboptimal and complicated by shared genetic risk factors and frequent co-pathology. In the present study we tested the ability of polygenic scores for Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease to differentiate individuals in a 2713-participant, pathologically defined sample. A dementia with Lewy bodies polygenic score that excluded apolipoprotein E due to its overlap with Alzheimer’s disease risk was specifically associated with at least limbic (transitional) Lewy-related pathology and a pathological diagnosis of dementia with Lewy bodies. An Alzheimer’s disease polygenic score was associated with neuritic plaques and neurofibrillary tangles but not Lewy-related pathology, and was most strongly associated with an Alzheimer’s pathological diagnosis. Our results indicate that an assessment of genetic risk may be useful to clinically distinguish between Alzheimer’s disease and dementia with Lewy bodies. Notably, we found no association with a Parkinson’s disease polygenic score, which aligns with evidence that dementia with Lewy bodies has a distinct genetic signature that can be exploited to improve clinical diagnoses.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Astrid Melani Suantio ◽  
Hian Liang Huang ◽  
Cecilia Sze Nga Kwok ◽  
Darren Cheng Han Teo ◽  
Minh Ha Nguyen

Sign in / Sign up

Export Citation Format

Share Document